FDA data Registry peer set 2 peers FDA shortage listed

Alternatives to palonosetron

FDA shortage status is active for palonosetron; 2 same-class SPL records are listed below for registry comparison only.

Brand: Aloxi

5-HT3 Receptor Antagonist (Antiemetic) Prescription 2 alternatives found

palonosetron class peers while FDA lists an active shortage

palonosetron (Aloxi) is on an FDA shortage listing while 2 other 5-HT3 Receptor Antagonist (Antiemetic) SPL records remain in this registry peer set (class inventory 3). Labeled indication field for palonosetron: Palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy.

Top FAERS reaction fields for palonosetron total 2,414 reports across 10 reactions, set beside granisetron, ondansetron. Counts are exposure-weighted submissions, not per-patient risk.

About palonosetron

Palonosetron is a medicine that helps prevent nausea and vomiting. It is often used before, during, and after chemotherapy or surgery.

Used for: Palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy. It can prevent these side effects from both the first treatment and any repeat treatments. Palonosetron is also used to prevent nausea and vomiting after surgery.

2 5-HT3 Receptor Antagonist (Antiemetic) peers (wide set)

Compare palonosetron vs granisetron side-by-side →

palonosetron vs granisetron & ondansetron · FAERS reaction fields

FAERS top-reaction field "Nausea" shows the widest count spread between palonosetron and granisetron, ondansetron in this extract (11,155-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect palonosetron granisetronondansetron
Nausea 399 1,305 11,554
Fatigue 249 549 8,199
Febrile Neutropenia 249 718 4,495
Diarrhoea 246 709 7,791
Vomiting 246 754 7,326
Neutropenia 245 474 -
Alopecia 223 - -
Dyspnoea 194 592 4,707

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

palonosetron shortage vs 5-HT3 Receptor Antagonist (Antiemetic) peer index

Shortage status

FDA shortage listing is active for palonosetron (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.

Frequently Asked Questions

Does FDA list a shortage for palonosetron while peers remain indexed?
Yes - palonosetron matched an active FDA shortage listing (To Be Discontinued) while 2 other 5-HT3 Receptor Antagonist (Antiemetic) SPL records remain in this peer index for field comparison only.

Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full palonosetron profile →

Field note for palonosetron: see also the generic vs brand label guide when reading Aloxi SPL strings.